The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Breyanzi. The marketing authorisation… read more.
Eli Lilly and Company announced results from the primary overall survival (OS) analysis of the Phase III monarchE trial showing that two years of adjuvant Verzenio plus endocrine… read more.
Researchers report success in using pazopanib to treat young patients diagnosed with deadly Ewing’s sarcoma. They published their findings on Oct. 23, 2025 in Frontiers in Oncology As… read more.
Lung cancer screening might be the best-kept secret in health care today. Only about 16 percent of those who are eligible in the U.S. get screened for lung… read more.
Researchers report that overall survival is significantly longer among prostate cancer patients at high-risk of biochemical recurrence who are treated with combination enzalutamide and leuprolide rather than with… read more.
Nuvectis Pharma Inc, a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,… read more.
Actinium Pharmaceuticals, Inc.), a leader in the development of differentiated targeted radiotherapies announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC)… read more.
Gilead Sciences, Inc. and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for… read more.
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting,… read more.
AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October… read more.
Roche announced that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held 17-21… read more.
At the European Society for Medical Oncology (ESMO) Congress 2025, Boehringer Ingelheim will present new data from across its robust oncology pipeline, including non-small cell lung cancer (NSCLC)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
